TIDMMEDG
Medgenics Inc
18 May 2012
Press Release 18 May 2012
Medgenics To Present at the 11th Annual ILSI BIOMED 2012
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the
"Company"), the developer of the novel Biopump(TM) technology for
the sustained production and delivery of therapeutic proteins in
patients using their own tissue, today announced that Andrew L.
Pearlman, Ph.D., the Company's President and CEO, will present a
corporate overview at the 11(th) Annual Israeli Life Sciences
Industry Biomed 2011 Conference taking place at the David
Intercontinental Hotel in Tel Aviv, Israel from May 21-23, 2012.
Dr. Pearlman will deliver the Company's presentation on Monday, May
21 at 4:30 p.m. (local time) in Hall C.
ILSI-Biomed 2012 follows the success of its previous annual
conferences: last year's event drew 6,000 industry professionals,
engineers and scientists, with 1,000 participants from 42 countries
and more than 2,500 one-on-one meetings. This provides Medgenics
with significant opportunity to showcase before a global audience
of relevant industry leaders its novel, tissue-based technology
platform, the Biopump, for the sustained production and dosing of
therapeutic proteins using a patient's own tissue.
About Israeli Life Sciences Industry
The Israel Life Science Industry (ILSI) is composed of medical
device, biotechnology, pharmaceutical and medical service
companies, universities and private research institutions, and
providers of services to the industry such as venture capitalists,
lawyers, accountants and incubators. The goal of ILSI is to develop
solidinformation about the medical research and manufacturing
community in Israel, and to make that information available to
political leaders, the news media, venture capitalists, investment
bankers, and the public. It is exactly this information required by
potential investors be it strategic corporate players or financial
investors worldwide. The intent is to demonstrate that medical
research and manufacturing is a major contributor to Israel's
economy - with unusually great potential for financial growth and
job creation.
About Medgenics
Medgenics is developing and commercializing Biopump(TM), a
proprietary tissue-based platform technology for the sustained
production and delivery of therapeutic proteins using the patient's
own dermal skin biopsy for the treatment of a range of chronic
diseases including anemia, hepatitis and hemophilia, among others.
Medgenics believes this approach has multiple benefits compared
with current treatments, which include regular and costly
injections of therapeutic proteins.
Medgenics has three long-acting protein therapy products in
development based on this technology:
-- EPODURE(TM) to produce and deliver erythropoietin for many
months from a single administration, has demonstrated elevation and
stabilization of hemoglobin levels in anemic patients for six to
more than 36 months in a Phase I/II dose-ranging trial, and has
received approval of a Phase IIa trial in dialysis patients due to
launch in Q2 2012 in Israel. An Investigational New Drug
application has been cleared by the FDA to initiate a Phase IIb
study to evaluate the safety and efficacy of EPODURE in the
treatment of anemia in dialysis patients in the U.S.
-- INFRADURE(TM) for sustained production and delivery of
interferon-alpha for use in the treatment of hepatitis is awaiting
final approval of two Phase I/II trials in Israel in hepatitis C,
slated to commence in Q3 2012, and is filed for Orphan Drug
Designation with the FDA to treat hepatitis D.
-- HEMODURE(TM) for sustained production and delivery of
clotting Factor VIII therapy for the sustained prophylactic
treatment of hemophilia is now in development.
Medgenics is focused on the development and manufacturing of its
innovative Biopumps, aiming to bring them to market via strategic
partnerships with major pharmaceutical and/or medical device
companies.
In addition to treatments for anemia, hepatitis and hemophilia,
Medgenics plans to develop and/or out-license a pipeline of future
Biopump products targeting the large and rapidly growing global
protein therapy market, which is forecast to reach $132 billion in
2013. Other potential applications for Biopumps include multiple
sclerosis, arthritis, pediatric growth hormone deficiency, obesity
and diabetes.
Forward-looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and as that term is defined
in the Private Securities Litigation Reform Act of 1995, which
include all statements other than statements of historical fact,
including (without limitation) those regarding the Company's
financial position, its development and business strategy, its
product candidates and the plans and objectives of management for
future operations. The Company intends that such forward-looking
statements be subject to the safe harbors created by such laws.
Forward-looking statements are sometimes identified by their use of
the terms and phrases such as "estimate," "project," "intend, "
"forecast," "anticipate," "plan," "planning, "expect," "believe,"
"will," "will likely," "should," "could," "would," "may" or the
negative of such terms and other comparable terminology. All such
forward-looking statements are based on current expectations and
are subject to risks and uncertainties. Should any of these risks
or uncertainties materialize, or should any of the Company's
assumptions prove incorrect, actual results may differ materially
from those included within these forward-looking statements.
Accordingly, no undue reliance should be placed on these
forward-looking statements, which speak only as of the date made.
The Company expressly disclaims any obligation or undertaking to
disseminate any updates or revisions to any forward-looking
statements contained herein to reflect any change in the Company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
As a result of these factors, the events described in the
forward-looking statements contained in this release may not
occur.
For further information, contact:
Medgenics, Inc. Phone: +972 4 902 8900
Dr. Andrew L. Pearlman
andrew.pearlman@medgenics.com
LHA Phone: 212-838-3777
Anne Marie Fields
afields@lhai.com
@LHA_IR_PR
Abchurch Communications Phone: +44 207 398 7719
Adam Michael
Joanne Shears
Jamie Hooper
jamie.hooper@abchurch-group.com
Religare Capital Markets UK Ltd. Phone: +44 207 444 0800
(NOMAD)
David Porter
Richard Thompson
SVS Securities plc (Joint Broker) Phone: +44 207 638 5600
Alex Mattey
Ian Callaway
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAAPMRTMBABMBT
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jul 2023 to Jul 2024